Completed
PHASE1
INTERVENTIONAL
NCT04958109
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an oral glucose tolerance test
Detailed Description
Assignment: Each study subject will serve as their own control. The order of the visits will be randomized. Delivery of Interventions: * Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories. * During the inpatient study, the subjects will * Undergo a 16-hour kisspeptin infusion * Undergo an oral glucose tolerance test
Interventions
Name:
Oral Glucose Tolerance Test
Type:
DIAGNOSTIC_TEST
Description:
Administration of a 75 gm oral glucose tolerance test
Name:
Kisspeptin
Type:
DRUG
Description:
Intravenous administration of kisspeptin 112-121 x 16 hours
Name:
Placebo
Type:
DRUG
Description:
Intravenous administration of Placebo 16 hours
Primary Outcomes
Measure:
Oral Glucose Sensitivity Index (Kisspeptin-Placebo)
TimeFrame:
3 hours
Description:
Change in Oral glucose Sensitivity Index between kisspeptin and placebo arms in oral glucose tolerance test
Trial Information
NCT ID
NCT04958109
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Massachusetts General Hospital
Last Updated
December 15, 2025